Shenzhen Weiguang Biological Products Co Ltd
SZSE:002880
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Shenzhen Weiguang Biological Products Co Ltd
Capital Expenditures
Shenzhen Weiguang Biological Products Co Ltd
Capital Expenditures Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Shenzhen Weiguang Biological Products Co Ltd
SZSE:002880
|
Capital Expenditures
-¥196.7m
|
CAGR 3-Years
14%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Capital Expenditures
-¥1.4B
|
CAGR 3-Years
15%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
|
Innovent Biologics Inc
HKEX:1801
|
Capital Expenditures
-¥1.2B
|
CAGR 3-Years
5%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
N/A
|
|
|
RemeGen Co Ltd
SSE:688331
|
Capital Expenditures
-¥200m
|
CAGR 3-Years
36%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
Capital Expenditures
-¥793m
|
CAGR 3-Years
0%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
|
S
|
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
|
Capital Expenditures
-¥126.3m
|
CAGR 3-Years
-48%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Shenzhen Weiguang Biological Products Co Ltd
Glance View
Shenzhen Weiguang Biological Products Co., Ltd. engages in the manufacturing, research and development of drug and blood products. The company is headquartered in Shenzhen, Guangdong and currently employs 759 full-time employees. The company went IPO on 2017-06-16. The Company’s primary products are blood products, including the human serum albumin, human immunoglobulin, intravenous human immunoglobulin, freeze-dried intravenous human immunoglobulin, hepatitis B human immunoglobulin, Rabies immunoglobulin, tetanus immunoglobulin, histamine human immunoglobulin, and human fibrinogen. The firm mainly operates its businesses in domestic market.
See Also
What is Shenzhen Weiguang Biological Products Co Ltd's Capital Expenditures?
Capital Expenditures
-196.7m
CNY
Based on the financial report for Sep 30, 2025, Shenzhen Weiguang Biological Products Co Ltd's Capital Expenditures amounts to -196.7m CNY.
What is Shenzhen Weiguang Biological Products Co Ltd's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
-7%
Over the last year, the Capital Expenditures growth was 37%. The average annual Capital Expenditures growth rates for Shenzhen Weiguang Biological Products Co Ltd have been 14% over the past three years , -7% over the past five years .
